147 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
ARRY Array BioPharma Inc. $11.33 $1.95B N/A
Article Searches
JF's Core Biotech Buys #15: Removal Of A Key Overhang, Buying Weakness In I-O, Updates And Adding To 2 Positions https://seekingalpha.com/article/4173708-jfs-core-biotech-buys-15-removal-key-overhang-buying-weakness-o-updates-adding-2-positions?source=feed_all_articles May 14, 2018 - Although this series is focused on the long term I continue to be pleased with our performance so far.President Trump´s speech on drug prices removed a key overhang for biotech (please see my blog pos
Lucky Seven: Achaogen Likely To Bounce Back https://seekingalpha.com/article/4173647-lucky-seven-achaogen-likely-bounce-back?source=feed_sector_healthcare May 14, 2018 - We have reasons to believe Achaogen will bounce back and resume its upward momentum. In anticipation of this, Achaogen will replace Omeros in the Lucky Seven portfolio. Shares in Global Blood Therapeu
Lucky Seven: Omeros Pops, Exelixis Drops On Phase 3 Flop https://seekingalpha.com/article/4173163-lucky-seven-omeros-pops-exelixis-drops-phase-3-flop?source=feed May 12, 2018 - Viking Therapeutics faces key resistance.Omeros reports Q1 earnings - continues its strong ascent.Array BioPharma springs off support.Exelixis, in collaboration with Roche, failed a phase 3 trial. The
Array BioPharma (ARRY) in Focus: Stock Moves 5.5% Higher http://www.zacks.com/stock/news/303223/array-biopharma-arry-in-focus-stock-moves-55-higher?cid=CS-ZC-FT-303223 May 11, 2018 - Array BioPharma (ARRY) was a big mover last session, as the company saw its shares rise more than 5% on the day amid huge volumes.
Array BioPharma's (ARRY) CEO Ron Squarer on Q3 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4171824-array-biopharmas-arry-ceo-ron-squarer-q3-2018-results-earnings-call-transcript?source=feed_all_articles May 09, 2018 - Array BioPharma (NASDAQ:ARRY) Q3 2018 Earnings Conference Call May 9, 2018 9:00 AM ET Executives Andrea Flynn - Senior Director, Investor Relations and Corporate Communications Ron Squarer - Chief Exe
Array BioPharma Inc. 2018 Q3 - Results - Earnings Call Slides https://seekingalpha.com/article/4171679-array-biopharma-inc-2018-q3-results-earnings-call-slides?source=feed_all_articles May 09, 2018 - The following slide deck was published by Array BioPharma Inc. in conjunction with their 2018 Q3 earnings call.
Bvf Inc Buys Ironwood Pharmaceuticals Inc, Merus NV, Xencor Inc, Sells Array BioPharma Inc, ... http://www.gurufocus.com/news/678059/bvf-inc-buys-ironwood-pharmaceuticals-inc-merus-nv-xencor-inc-sells-array-biopharma-inc-cytomx-therapeutics-inc-anaptysbio-inc May 07, 2018 - Bvf Inc Buys Ironwood Pharmaceuticals Inc, Merus NV, Xencor Inc, Sells Array BioPharma Inc, CytomX Therapeutics Inc, AnaptysBio Inc, Stocks: CRVS,IMDZ,PIRS,FWP,VSTM,PTGX,IRWD,MRUS,XNCR,RCUS,A, release date:May 07, 2018
JF's Core Biotech Buys #14: Introducing Our Final 2 Positions & Taking Advantage Of Weakness In The I-O Space https://seekingalpha.com/article/4170858-jfs-core-biotech-buys-14-introducing-final-2-positions-and-taking-advantage-weakness-o-space?source=feed_all_articles May 07, 2018 - The M&A theme appears set to continue in the spotlight this year, with Gilead to put cash to work and Takeda likely to come to terms with Shire.President Trump´s drug pricing speech is expected soon a
Reader Inquiry: Is Recent Weakness In Array BioPharma Warranted? https://seekingalpha.com/article/4170365-reader-inquiry-recent-weakness-array-biopharma-warranted?source=feed_all_articles May 06, 2018 - The stock has performed admirably since my initial article. However, it´s currently the biggest loser in the Core Biotech model account. I provide a recap of the bullish thesis and recent developments
Will Tinder Gold Drive Match Group's (MTCH) Q1 Earnings? http://www.zacks.com/stock/news/302408/will-tinder-gold-drive-match-groups-mtch-q1-earnings?cid=CS-ZC-FT-302408 May 04, 2018 - Match Group's (MTCH) first-quarter 2018 earnings to benefit from steady market traction of apps like Tinder, which are driving higher subscriber growth.

Pages: 1234567...15

<Page 2>